Stéphane Bancel

Stéphane Bancel is a French business executive and biotechnology entrepreneur. - **Background:** He earned an engineering degree from École Centrale Paris and an MBA from Harvard Business School. Before Moderna, he held management roles at Eli Lilly and served as CEO of French diagnostics company bioMérieux. - **Current role:** He has been **CEO of Moderna since 2011**, leading the company’s development and commercialization of mRNA-based medicines and vaccines. - **Notable work:** Under his leadership, Moderna advanced its mRNA platform and developed **Spikevax**, one of the first widely authorized COVID-19 vaccines. He has also overseen Moderna’s expansion into vaccines for respiratory viruses, cancer therapies, and other diseases.

Stéphane Bancel is a **French biotech executive** best known as the **CEO of Moderna**, the U.S.-based mRNA biotechnology company behind one of the first COVID-19 vaccines.[1][2] He studied engineering at **CentraleSupélec** and **chemical engineering at the University of Minnesota**, and later earned an **MBA from Harvard Business School**.[1][5][6] Before Moderna, he held senior roles at **bioMérieux** and **Eli Lilly**, including serving as **CEO of bioMérieux** from 2007 to 2011.[1][5][11] At Moderna, where he became CEO in **2011**, Bancel has been central to the company’s growth and its development of **mRNA therapeutics and vaccines**, especially the **COVID-19 vaccine**.[2][5][14]

# Stéphane Bancel Stéphane Bancel is the CEO of Moderna, a biotechnology company focused on messenger RNA (mRNA) therapeutics. **Background:** - French-born entrepreneur with a background in business and engineering - Previously held leadership roles at other biotech and healthcare companies before joining Moderna **Current Role:** - CEO of Moderna since 2011 - Led the company through its development of mRNA vaccine technology **Notable Work:** - Most prominently known for leading Moderna's development of an mRNA COVID-19 vaccine, which received emergency authorization in late 2020 and became widely deployed globally - Positioned Moderna as a major player in mRNA-based therapeutics beyond vaccines - Took the company public in 2018 Bancel is generally credited with building Moderna into one of the most valuable biotech companies, though the company and its leadership have also faced scrutiny regarding vaccine pricing and other business practices.

**Stéphane Bancel** is a French businessman and executive best known for his leadership in the biotechnology sector. * **Current Role:** He has served as the Chief Executive Officer (CEO) of **Moderna** since 2011, leading the company through its transformation from an early-stage research startup into a global pharmaceutical giant. * **Background:** Bancel earned a Master of Engineering from École Centrale de Paris, a Master of Science in chemical engineering from the University of Massachusetts Lowell, and an MBA from Harvard Business School. Before joining Moderna, he served as the CEO of the French diagnostics company bioMérieux and as managing director of Eli Lilly in Belgium. * **Notable Work:** Under his leadership, Moderna developed its proprietary mRNA platform and successfully created and commercialized its mRNA-based COVID-19 vaccine (Spikevax) in record time during the pandemic, a milestone that significantly altered the landscape of modern vaccinology and medicine.

Stéphane Bancel is a French-American businessman and the current CEO of Moderna Therapeutics, a biotechnology company based in Cambridge, Massachusetts. Here is a concise factual summary of his background and career: **Background:** Bancel was born in 1965 in France. He holds a Master's degree in Engineering from the École Polytechnique in Paris and an MBA from Harvard Business School. **Current Role:** Bancel has been the CEO of Moderna Therapeutics since 2011, where he has led the company's development of messenger RNA (mRNA) therapeutics and vaccines, including the COVID-19 vaccine mRNA-1273. **Notable Work:** Under Bancel's leadership, Moderna has made significant advancements in mRNA technology, including the development of a COVID-19 vaccine that has been authorized for emergency use in numerous countries. The company's vaccine has been hailed as a key contributor to the fight against the COVID-19 pandemic. Bancel has also been a vocal advocate for the use of mRNA technology to address a range of diseases, including infectious diseases, cancer, and rare genetic disorders. Bancel has received numerous awards and recognitions for his leadership and contributions to the field of biotechnology, including being named one of the most influential people in the world by TIME Magazine in 2021.